BIO 2019 Notebook: Merck On Finding The Right Balance, NORD On Patient Engagement, Sandoz On The Next Wave Of Biosimilars

 
• By Joseph Haas and Sue Sutter
  
Bio 2019 Notebook for Pink
FDA is helping NORD obtain funding for longitudinal natural history studies of rare diseases that lack approved drug therapy.

More from Biosimilars

More from Biosimilars & Generics